Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women with Severe PPD
Details : LPCN 1154A (Brexanolone) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Depression, Postpartum.
Product Name : LPCN 1154A
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Starts Phase 3 Outpatient Trial of LPCN 1154 for Postpartum Depression
Details : LPCN 1154 (brexanolone) is an oral neurosteroid, a positive allosteric modulator of GABAA receptors. It is being evaluated for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Details : LPCN 1154 (brexanolone) is an oral neurosteroid, a positive allosteric modulator of GABAA receptors. It is being evaluated in phase 2 clinical trials for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | Sage Therapeutics | RTI International | Yale University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brexanolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alcoholism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 30, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | Sage Therapeutics | RTI International | Yale University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Completes Dosing in Pivotal Study for LPCN 1154 Postpartum Depression Candidate
Details : LPCN 1154 (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator. It is being evaluated for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Details : LPCN 1154 (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator. It is being evaluated for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
Details : LPCN 1154 (brexanolone) is an oral neurosteroid, a positive allosteric modulator of GABAA receptors. It is being evaluated in phase 2 clinical trials for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2024
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
Details : LPCN 1154 is targeted to be a differentiated oral option with rapid-onset, robust efficacy, and short treatment duration as a mono or add-on therapy for patients with unresolved depression symptoms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154
Details : LPCN 1154 is an oral formulation of the neuroactive steroid brexanolone for self-administration in development for the treatment of PPD. The active moiety in LPCN 1154 is a bioidentical positive allosteric modulator of y-aminobutyric acid (GABA) receptor...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2023
Lead Product(s) : Brexanolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brexanolone
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
Details : Brexanolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tinnitus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : Brexanolone
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable